Apr. 24 at 12:10 PM
$ALCY's merger target Alcyone scores strategic financing and Phase 1/2 data showing CLN-301 gene therapy halts CLN3 Batten disease progression. Patients maintained skills vs 8.6-point natural decline. Biogen partnership on ThecaFlex delivery adds platform value. SPAC investors betting big on this rare disease moonshot.
https://www.prnewswire.com/news-releases/alcyone-therapeutics-announces-strategic-financing-to-advance-an-expanded-pipeline-of-pediatric-focused-precision-therapeutics-for-severe-neurological-diseases-302436946.html